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Martin J HoogduijnAbstract
Mesenchymal stromal cells (MSCs) are considered to be
promising agents for the treatment of immunological
disease. Although originally identified as precursor cells
for mesenchymal lineages, in vitro studies have
demonstrated that MSCs possess diverse immune
regulatory capacities. Pre-clinical models have shown
beneficial effects of MSCs in multiple immunological
diseases and a number of phase 1/2 clinical trials carried
out so far have reported signs of immune modulation
after MSC infusion. These data indicate that MSCs play a
central role in the immune response. This raises the
academic question whether MSCs are immune cells
or whether they are tissue precursor cells with
immunoregulatory capacity. Correct understanding
of the immunological properties and origin of MSCs
will aid in the appropriate and safe use of the
cells for clinical therapy. In this review the whole
spectrum of immunological properties of MSCs is
discussed with the aim of determining the position
of MSCs in the immune system.cells [11]. Studies in animal models have shown that
MSCs can reduce disease progression and/or severity ofIntroduction
Mesenchymal stromal cells (MSCs) were originally
identified as precursors for cells of the osteogenic
lineage [1]. They were later discovered to be able to
differentiate also into the chondrogenic, adipogenic
and myogenic lineages [2]. Within the scientific com-
munity there is some controversy about the naming
and precise definition of MSCs. The term 'mesenchy-
mal stromal cell' is used in parallel with 'mesenchymal
stem cell' and 'multipotent mesenchymal stromal cell'.
MSCs are in fact a heterogeneous population of cells
that express CD73, CD90 and CD105 and lack the haem-
atopoietic lineage markers CD45, CD34, CD11c, CD14,
CD19, CD79A and HLA-DR [3]. This immunophenotype,Correspondence: m.hoogduijn@erasmusmc.nl
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unless otherwise stated.however, covers various subsets of MSCs with different
phenotypes and different functions [4,5]. Cell isolation
procedures can, therefore, affect the cellular compos-
ition of MSC cultures. Culture conditions can have a
further impact on the phenotype and function of MSCs
[6]. This may affect study outcomes. Therefore, some
care should be taken in comparing the results of studies
using different MSC isolation and culture procedures.
In the bone marrow, MSCs have a supportive function
for the haematopoietic system and provide a niche for
haematopoietic progenitor cells to mature. The presence
of MSCs is not limited, however, to the bone marrow
and in other tissues, such as adipose tissue, muscle and
multiple organs, they provide support for tissue cells by
producing growth factors and matrix proteins. In
addition to their differentiation and tissue supportive
functions, MSCs have a well-established immune modu-
latory function. Several in vitro studies have demon-
strated that MSCs are able to effectively inhibit T
lymphocyte [7,8] and natural killer (NK) lymphocyte [9]
proliferation, impair antibody production by B cells [10],
and inhibit the maturation and function of dendritic
various immune diseases such as collagen-induced arth-
ritis [12], experimental autoimmune encephalomyelitis
[13], experimental colitis and sepsis [14]. It is believed
that MSCs mediate their beneficial effects by modulating
the immune system, although the exact mechanisms of
immunomodulation by MSCs in vivo are not clear. Even
though there is abundant evidence that MSCs modulate
immune responses by interacting with cells of the im-
mune system, the question is whether MSCs themselves
should be perceived as true immune cells. Do MSCs ex-
ercise immune functions like immune cells do and what
is their response to pathogens? In this review, the vari-
ous immunological roles of MSCs are discussed, culmin-
ating in a conclusion on the position of MSCs in the
immune system.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Interaction with immune cells
MSCs interact with cells of the immune system via a pleth-
ora of mechanisms. They secrete anti-inflammatory factors
such as transforming growth factor β (TGF-β), hepatocyte
growth factor (HGF) and prostaglandin-E2 (PGE-2) [7,8],
and they express cell surface molecules with immunosup-
pressive properties such as programmed death ligand 1
(PD-L1) and Fas ligand [15,16], via which they directly tar-
get immune cells and inhibit their activation and function.
MSCs furthermore attract immune cells by secreting a
broad mixture of chemokines. In particular, the neutrophil
chemo-attractant interleukin (IL)-8 and the monocyte-
attractant CCL2 are secreted in high amounts by MSCs
[17]. Chemokine secretion by MSCs may act in a dual way
to modulate the immune response. Reactive immune cells
will be attracted and exert their immunological function,
but at the same time they may be targeted by MSCs and
inhibited in their function. There is evidence that MSCs
bind activated immune cells [18], potentially to keep them
at a close distance to enhance the effect of their immuno-
suppressive actions. The immunoregulatory effects of MSCs
are not only directed directly against efxfector immune cells.
MSCs do not themselves produce the anti-inflammatory
cytokine IL-10, but they induce other cell types to do this
[19]. Via the secretion of TGF-β and other factors MSCs
also promote the induction of regulatory T cells [20], regula-
tory macrophages [21] and regulatory B cells [22], and in
this way pass on their immunosuppressive effects to other
cell types that exert different mechanisms of immune sup-
pression. A schematic overview of the interactions between
MSCs and immune cells is depicted in Figure 1.
Metabolic control of the immune system
In addition to the well described mechanisms of immune
modulation via cytokines, chemokines and inhibitory co-
stimulation molecules, MSCs are actively involved in the
metabolic control of the immune system. MSCs can be in-
duced to express the enzyme indoleamine 2,3-dioxygenase
(IDO), which has a potent capacity to inhibit lymphocyte
proliferation by metabolising L-tryptophan to L-kynurenine
[23]. Reduced levels of L-tryptophan suppress lymphocyte
proliferation and, simultaneously, high levels of L-
kynurenine impose a block on proliferation as well. Fur-
thermore, MSCs strongly and constitutively express CD73
[3], which acts in concordance with CD39 on regulatory T
cells to metabolise ATP to adenosine, thereby taking away
the inflammation-promoting effect of ATP [24]. Metabolic
control of the immune response also occurs through other
mechanisms, such as L-arginine metabolism, which is
employed by myeloid cells to inhibit lymphocyte activities
[25]. It is unknown whether MSCs make use of this path-
way to regulate immune cells.Adaptation to inflammatory conditions
MSCs can be considered as genuine regulators of the
immune system because they adapt their immunoregula-
tory properties to the local immunological milieu. MSCs
sense inflammation and in response to pro-inflammatory
cytokines, in particular interferon-γ and tumour necrosis
factor (TNF)-α, they change their immunological role. In
the absence of inflammation, MSCs promote the survival
of T lymphocytes [26] and can even stimulate their pro-
liferation, partly via IL-6-dependent mechanisms [27].
MSCs have recently been identified as producers of IL-7
[28], which stimulates the differentiation of haematopoi-
etic cells into lymphoid cells but also promotes the pro-
liferation of lymphocytes. Once placed under immune
activating conditions, MSCs upregulate the expression of
IDO, HGF, PD-L1, TNF-stimulated gene 6 protein and
PGE2-producing cyclooxygenase 2 [29] as part of im-
munological negative feedback loops [30]. MSCs adapted
to inflammatory conditions will inhibit immune cell acti-
vation and proliferation [31] and increase their regulatory
T cell-inducing capacity [32]. Even though the expression
of pro-inflammatory factors such as IL-6, IL-7 and several
chemokines by MSCs is also increased under inflamma-
tory conditions, the immunosuppressive effects of MSCs
prevail under these conditions. MSCs thus play a central
role in maintaining immune homeostasis by interacting
with immune cells via cytokines, chemokines, cell surface
molecules and metabolic pathways. The question is whether
this is sufficient to qualify MSCs as immune cells. Strictly
speaking, an immune cell protects organisms against patho-
gens, cleans up cell debris, and removes diseased cells. The
MSC functions described above steer the activities of the
immune system but do not by themselves represent core
immune functions. Do MSCs possess these properties?
Role of mesenchymal stromal cells in immune
defence
Immune cell effector functions
Immune cells fight diseased cells and pathogens by cyto-
toxic activity, antibody production, and phagocytosis.
MSCs do not express granzymes or perforins and do not
produce antibodies and are not, therefore, capable of cyto-
toxic activity or participation in the humoral defence.
There is some evidence, however, that MSCs possess
phagocytic properties. It was shown that MSCs can phago-
cytise apoptotic cells, which as a result enhances their
osteogenic differentiation capacity [33]. MSCs that phago-
cytised apoptotic cells increased chemokine expression
and induced Th17 cells, suggesting that phagocytosis leads
to an immune-activating response in MSCs. More data on
the phagocytic activity of MSCs are not available at
present, which leaves their role as a phagocytic cell un-
clear. Overall, there is no overwhelming evidence that
MSCs act as effector cells in the immune system.
Figure 1 Overview of the interactions between mesenchymal stromal cells (MSCs) and immune cells. MSCs secrete cytokines (including
transforming growth factor β, hepatocyte growth factor, IL-6, IL-7), chemokines (CCL2, IL-8) and prostaglandins (prostaglandin-E2), and express
proliferation inhibitory cell surface molecules (programmed death ligand 1, Fas ligand) and metabolic enzymes (indoleamine 2,3-dioxygenase,
CD73) that target immune cells in various ways. APC, antigen-presenting cell; NK, natural killer; TLR, Toll-like receptor.
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Whereas MSCs may not have immune cell effector
functions, they can play a role in the initiation of im-
mune responses. MSCs have the capacity, like all nucle-
ated cells, to present antigen via major histocompatibility
complex (MHC) class I molecules, which are constitu-
tively expressed on MSCs. Antigens presented via MHC
class I are endogenous antigens and their presentation
serves the recognition of pathogen-infected or trans-
formed cells by CD8+ cytotoxic cells. Under inflammatory
conditions, MSCs also express MHC class II and thereby
gain the capacity to present exogenous antigens to T cells
[34,35], a property shared by professional antigen-
presenting cells such as dendritic cells and macrophages.
Interferon-γ-stimulated MSCs furthermore possess MHC
class II-mediated antigen processing capacity [36]. Under
inflammatory conditions MSCs can thus present antigens
from their environment and induce adaptive immune re-
sponses by activation of CD4+ T cells. In addition, MSCs
can cross-present antigens via their MHC class I mole-
cules and process antigen via proteasome- and transporter
molecule-dependent mechanisms [37]. Via this route
MSCs can initiate CD8+ T-cell responses to exogenous an-
tigens. Although the ability to process and present anti-
gens would appear to be a typical immune cell function, is
it not unique to immune cells. Endothelial cells and fibro-
blasts, like MSCs, upregulate MHC class II under inflam-
matory conditions, and under these conditions they arepotent stimulators of CD4+ T-cell responses [38]. Endo-
thelial cells furthermore have the capacity to cross-present
antigens via MHC class I [39]. Antigen presentation under
inflammatory conditions is thus a capacity shared by dif-
ferent types of tissue cells.
Response to pathogens
MSCs do not possess receptors that recognise specific
antigens, such as cells of the adaptive immune system
do via T- and B-cell receptors. Recognition of antigen by
innate immune cells is mediated via a broad range of pat-
tern recognition receptors. MSCs express certain pattern
recognition receptors, including NOD-like receptors [40]
and Toll-like receptors (TLRs) [41]. Inflammatory condi-
tions affect the expression of TLRs on MSCs [42] and
TLR activation may lead to an inhibition of the immuno-
suppressive effects of MSCs, allowing T-cell responses to
build up [43], although there is also evidence that the im-
munosuppressive effects of MSCs are increased by TLR
activation [44]. Via their pattern recognition receptors
MSCs recognise microbes and upon MSC-microbe associ-
ation they increase the expression of immunomodulatory
genes such as IL-6, IL-8 and cyclooxygenase-2 [45]. As a
result, the capacity of MSCs to inhibit T-cell proliferation
is enhanced, which could serve as a negative feedback loop
to protect against collateral damage of strong immune re-
sponses against microbes. MSCs furthermore exert direct
anti-microbial effects, as demonstrated in Escherichia coli-
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bacteria and secrete keratinocyte growth factor, which in-
duces monocytes to support the anti-microbial effect of
MSCs [46]. MSCs do thus participate in the defence
against microbial threats.
Migration to sites of inflammation
Immune cells migrate to sites of infection/inflammation
in response to chemokine attraction. Upon activation
they upregulate adhesion molecules and rolling and in-
vasion machinery and stick to the endothelium and mi-
grate in between endothelial cells and tissue cells to the
source of the chemokine production. MSCs also express
chemokine receptors and migrate in vitro in response to
chemotactic stimulation. This property is enhanced
under inflammatory conditions [47]. There is contro-
versy about the migratory ability of in vivo administered
MSCs, but for a comparison of the migratory properties
of MSCs with immune cells the migration of endogen-
ous MSCs should be discussed. Whereas MSCs have
been detected in the circulation in animal models, there
is little evidence for the presence of MSCs in the human
circulation [48], except for under conditions where the
MSC niche is disrupted, such as in trauma patients
[49,50]. A study has demonstrated that human MSCs
can egress from adipose tissue to migrate to lymph
nodes [51], suggesting that MSCs may avoid the blood
stream as a means of transportation and instead use the
lymphatic system. Via the lymphatic system MSCs
would not, however, reach sites of tissue inflammation.
In contrast to neutrophils, macrophages and lympho-
cytes, the need for MSC recruitment from distant sites
to inflamed tissue may not be essential as MSCs are
already present in all tissues. MSCs may be recruited lo-
cally to increase their presence at inflamed sites.
MSCs thus certainly play a role in the immune de-
fence, but their tasks are not as specialised as those of
other types of immune cells. MSCs rather support vari-
ous aspects of the immune response.
The origin of mesenchymal stromal cells
Mesenchymal origin
During embryonic development MSCs are derived from
the mesodermal germ layer; the mesoderm forms the con-
nective tissue and the haematopoietic system. Whereas all
traditional immune cells are of haematopoietic origin, the
developmental origin of MSCs is not entirely clear and a
matter of debate. The hypothesis that MSCs are of bone
marrow stromal origin and migrate from there to periph-
eral tissues to occupy their place as regenerative and im-
munomodulatory cells during adulthood is outdated by
data showing that MSCs of recipient origin are not found
in transplanted organs even many years after transplant-
ation [52] and the absence of MSCs in the circulation ofhealthy individuals and patients with severe organ injury
[50]. The discovery in multiple organs of cells around
blood vessels that lack haematopoietic, endothelial, and
myogenic cell markers but possess multi-lineage differen-
tiation capacity and express MSC markers has suggested
that MSCs are of perivascular origin [53]. More recently,
it was demonstrated that tooth MSCs are derived from
peripheral nerve-associated glial cells [54]. These results
suggest that MSCs are distributed throughout the body
during development and reside in their specific niche dur-
ing adulthood from where they act locally to mediate re-
generative and immunomodulatory processes.
Haematopoietic origin?
Although the non-haematological origin of MSCs is gen-
erally accepted, data suggest that the distinction between
haematopoietic and non-haematopoietic cells may not be
as sharp as commonly believed. A suggestion for this may
arise from the fact that adipose tissue-derived MSCs ex-
press the haematopoietic stem cell marker CD34. Further-
more, elegant experiments carried out a decade ago
demonstrated that the transplantation of single green
fluorescent protein (GFP)-expressing haematopoietic stem
cells in mice led to the generation of GFP-positive micro-
glial and perivascular cells [55], cells that are members of
the MSC family. This would indicate that primitive haem-
atopoietic progenitor cells have the capacity to differenti-
ate into mesenchymal lineages. In further support of the
relationship of MSCs with the haematopoietic lineage are
the similarities that exist between fibroblasts and macro-
phages, as reviewed by Ogawa and colleagues [56]. Fibro-
blasts are derived from MSCs and like their precursor
cells they can adapt immunoregulatory properties and be-
come activated to secrete growth factors in case of tissue
injury. Macrophages in their turn can adapt similar regen-
erative properties and can home to injured tissue where
they stimulate repair processes [57]. In contrast to the idea
that MSCs are of haematopoietic origin, it is well known
that MSCs can be locally formed in tissue in a process
called epithelial to mesenchymal transition in which epi-
thelial cells give rise to MSCs in response to injury. Des-
pite the so far contrasting and insufficient data on the
classification of MSCs, the view that MSCs are of non-
haematopoietic origin is currently the most widely ac-
cepted. In this view, MSCs are thus of a different lineage
than classical immune cells.
Immunomodulatory therapy with mesenchymal
stromal cells
Infusion of mesenchymal stromal cells
The use of MSCs for immunomodulatory therapy for a
variety of immunological disorders is intensively studied.
Phase 1/2 clinical trials have been performed in graft ver-
sus host disease [58], organ transplantation [59,60], and
Note: This article is part of a thematic series on Biology
and clinical applications of stem cells for autoimmune and
musculoskeletal disorders, edited by Christian Jorgensen and
Anthony Hollander. Other articles in this series can be
found at http://www.biomedcentral.com/series/MSC
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matory bowel disease [61,62], systemic lupus erythemato-
sus [63,64] and multiple sclerosis [65]. Some of the studies
showed amelioration of disease severity, albeit the studies
were non-controlled. The use of MSCs for rheumatoid
arthritis has been examined in disease models by multiple
research groups [66] and a clinical study in 172 rheuma-
toid arthritis patients demonstrated that intravenous infu-
sion of allogeneic MSCs was feasible and safe and induced
a significant disease remission [67]. A placebo-controlled
study in chronic obstructive pulmonary disease demon-
strated that MSC therapy lowered C-reactive protein
levels, but did not affect disease indicators [68]. Although
the efficacy of MSC immunotherapy remains to be dem-
onstrated in larger placebo-controlled trials, in several of
the studies there were indications that the infusion of
MSCs leads to immunomodulatory effects. Do these ef-
fects prove that MSCs are immune cells? If one looks in
detail at the immunological effects that are induced by the
infusion of MSCs, it can be observed that MSCs induce
small inflammatory responses shortly after infusion [69],
whereas it is likely that the immunosuppressive effects of
MSCs take longer to occur. MSCs that are administered
via the intravenous route are, however, short-lived and the
large majority of them disappear after 24 hours [70]. It is
thus likely that the immunosuppressive effects of MSC
treatment are mediated by other cell types and there is in-
deed accumulating evidence that MSCs induce regulatory
T cells [71,72]. Thus, MSCs themselves may not be active
as immunoregulators after administration, but the regula-
tory immune cells that they induce may mediate these ef-
fects. In this sense, MSCs do not fit the definition of an
immune cell, but should rather been seen as coordinators
of the immune system.
Basically all clinical studies of the immunomodulatory
effect of MSCs have been performed after intravenous
infusion of MSCs. Intravenous infusion is the easiest and
therefore most commonly used route of administration
of MSCs, but it is possible that MSCs that are adminis-
tered via other routes act via different modes of action.
When MSCs are administered intramuscularly or are de-
livered via the arterial route to tissues of interest, they lo-
calise close to or even within sites of inflammation and
they may interact with immune cells in a more direct way
and may survive for a longer time. Whether MSCs admin-
istered into inflammatory sites act more like true immu-
noregulatory cells needs to be studied in more detail.
Immunogenicity of mesenchymal stromal cells
In contrast to immune cells, MSCs express low levels of
HLA class I and co-stimulatory molecules CD80 and
CD86 and are therefore low immunogenic. Like other
cells, MSCs do, however, induce allogeneic immune cell
responses, as demonstrated by the lysis of MSCs byHLA class I mismatched memory CD8+ T cells [73]. In
this sense MSCs do not behave differently from immune
cells. Different from immune cells, culture-expanded
MSCs are also susceptible to lysis by autologous IL-2-
activated NK cells [9]. Lysis by NK cells depends on the
relatively low expression of HLA class I molecules on
MSCs and the expression of activating NK cell receptor
ligands. Lysis by autologous NK cells indicates that
in vitro expansion induces the immunogenicity of MSCs
and, despite all their immune regulatory properties,
makes them targets of the immune defence themselves.
Conclusion
MSCs play a core role in maintaining immune homeo-
stasis in their niche in most, if not all, tissues by inter-
acting with antigen-presenting cells, phagocytic cells,
cytotoxic cells, B cells and helper T cells via soluble and
cell membrane-mediated mechanisms. This property is
maintained by cells of more differentiated mesenchymal
lineages, such as fibroblasts. Under inflammatory condi-
tions MSCs gain additional immunological functions,
such as antigen presentation. After culture expansion
and administration in humans or animals, MSCs acquire
a different function and trigger immunomodulatory re-
sponses by their short presence. Their developmental
origin and the limited migratory properties of MSCs,
which are associated with their role as precursor cells
for mesenchymal cells within tissues, show that MSCs
are not true immune cells. They are nevertheless omis-
sible for controlled functioning of the immune system
and there are promising prospects for the development
of MSC-based immune therapy in the near future.Abbreviations
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